Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Common Equity (2020 - 2023)

Historic Common Equity for Terns Pharmaceuticals (TERN) over the last 4 years, with Q3 2023 value amounting to $258.4 million.

  • Terns Pharmaceuticals' Common Equity rose 4068.23% to $258.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $258.4 million, marking a year-over-year increase of 4068.23%. This contributed to the annual value of $276.9 million for FY2022, which is 7276.22% up from last year.
  • According to the latest figures from Q3 2023, Terns Pharmaceuticals' Common Equity is $258.4 million, which was up 4068.23% from $274.2 million recorded in Q2 2023.
  • In the past 5 years, Terns Pharmaceuticals' Common Equity ranged from a high of $287.7 million in Q1 2023 and a low of -$119.8 million during Q3 2020
  • In the last 4 years, Terns Pharmaceuticals' Common Equity had a median value of $172.2 million in 2021 and averaged $121.6 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 29050.68% in 2021, then tumbled by 2432.89% in 2022.
  • Over the past 4 years, Terns Pharmaceuticals' Common Equity (Quarter) stood at -$117.4 million in 2020, then soared by 236.5% to $160.3 million in 2021, then surged by 72.76% to $276.9 million in 2022, then decreased by 6.69% to $258.4 million in 2023.
  • Its Common Equity stands at $258.4 million for Q3 2023, versus $274.2 million for Q2 2023 and $287.7 million for Q1 2023.